Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population

被引:76
作者
Simchoni, S
Friedman, E
Kaufman, B
Gershoni-Baruch, R
Orr-Urtreger, A
Kedar-Barnes, I
Shiri-Sverdlov, R
Dagan, E
Tsabari, S
Shohat, M
Catane, R
King, MC [1 ]
Lahad, A
Levy-Lahad, E
机构
[1] Univ Washington, Dept Med, Seattle, WA 98195 USA
[2] Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA
[3] Hebrew Univ Jerusalem, Sch Med, Dept Family Med, IL-91120 Jerusalem, Israel
[4] Hebrew Univ Jerusalem, Sch Med, Shaare Zedek Med Ctr, Med Genet Unit, IL-91031 Jerusalem, Israel
[5] Chaim Sheba Med Ctr, Oncogenet Unit, IL-52621 Tel Hashomer, Israel
[6] Chaim Sheba Med Ctr, Inst Oncol, IL-52621 Tel Hashomer, Israel
[7] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel
[8] Bruce Rappaport Fac Med, Rambam Med Ctr, Dept Human Genet, IL-31096 Haifa, Israel
[9] Tel Aviv Sourasky Med Ctr, Inst Genet, IL-64239 Tel Aviv, Israel
关键词
breast cancer; ovarian cancer; penetrance; hereditary cancer;
D O I
10.1073/pnas.0511301103
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
inherited mutations in BRCA1 and BRCA2 lead to significantly increased risks of breast and ovarian cancer. We used epidemiologic methods to evaluate the relative risks of breast cancer vs. ovarian cancer among women of Ashkenazi Jewish ancestry with inherited mutations in BRCA1 or BRCA2. The cancer of a family's index case (i.e., breast cancer vs. ovarian cancer) was significantly associated with site-specific risks of cancer in relatives known to carry mutations in BRCA1 or BRCA2. Specifically, breast cancer risks were higher among relatives of breast cancer index cases compared with relatives of ovarian cancer index cases [hazard ratio (HR) = 3.0, P < 0.001 for BRCA1 carriers and HR = 4.8, P = 0.017 for BRCA2 carriers], and ovarian cancer risks were higher among relatives of ovarian cancer index cases compared with relatives of breast cancer index cases (HR = 7.2, P = 0.001 for BRCA1 carriers and HIR = 15.8, P = 0.018 for BRCA2 carriers). Breast and ovarian cancer risks also increased with more recent year of birth. For each later decade of birth, risk increased 1.2-fold (P = 0.03). Effects of cancer site of the index case and of birth cohort were independent. These results suggest that both genetic and nongenetic factors modify cancer risks among BRCA1 and BRCA2 mutation carriers, and that genetic modifiers and other familial factors may influence risk specifically for either breast or ovarian cancer.
引用
收藏
页码:3770 / 3774
页数:5
相关论文
共 26 条
[1]   Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history:: A combined analysis of 22 studies [J].
Antoniou, A ;
Pharoah, PDP ;
Narod, S ;
Risch, HA ;
Eyfjord, JE ;
Hopper, JL ;
Loman, N ;
Olsson, H ;
Johannsson, O ;
Borg, Å ;
Pasini, B ;
Radice, P ;
Manoukian, S ;
Eccles, DM ;
Tang, N ;
Olah, E ;
Anton-Culver, H ;
Warner, E ;
Lubinski, J ;
Gronwald, J ;
Gorski, B ;
Tulinius, H ;
Thorlacius, S ;
Eerola, H ;
Nevanlinna, H ;
Syrjäkoski, K ;
Kallioniemi, OP ;
Thompson, D ;
Evans, C ;
Peto, J ;
Lalloo, F ;
Evans, DG ;
Easton, DF .
AMERICAN JOURNAL OF HUMAN GENETICS, 2003, 72 (05) :1117-1130
[2]  
Antoniou AC, 2000, GENET EPIDEMIOL, V18, P173
[3]   Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations:: a combined analysis of 22 population based studies [J].
Antoniou, AC ;
Pharoah, PDP ;
Narod, S ;
Risch, HA ;
Eyfjord, JE ;
Hopper, JL ;
Olsson, H ;
Johannsson, O ;
Borg, Å ;
Pasini, B ;
Radice, P ;
Manoukian, S ;
Eccles, DM ;
Tang, N ;
Olah, E ;
Anton-Culver, H ;
Warner, E ;
Lubinski, J ;
Gronwald, J ;
Gorski, B ;
Tulinius, H ;
Thorlacius, S ;
Eerola, H ;
Nevanlinna, H ;
Syrjäkoski, K ;
Kallioniemi, OP ;
Thompson, D ;
Evans, C ;
Peto, J ;
Lalloo, F ;
Evans, DG ;
Easton, DF .
JOURNAL OF MEDICAL GENETICS, 2005, 42 (07) :602-603
[4]   Androgen receptor CAG repeat length in Jewish Israeli women who are BRCA1/2 mutation carriers:: association with breast/ovarian cancer phenotype [J].
Dagan, E ;
Friedman, E ;
Paperna, T ;
Carmi, N ;
Gershoni-Baruch, R .
EUROPEAN JOURNAL OF HUMAN GENETICS, 2002, 10 (11) :724-728
[5]   Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene [J].
Gayther, SA ;
Mangion, J ;
Russell, P ;
Seal, S ;
Barfoot, R ;
Ponder, BAJ ;
Stratton, MR ;
Easton, D .
NATURE GENETICS, 1997, 15 (01) :103-105
[6]   BRCA1 and BRCA2 founder mutations in patients with bilateral breast cancer [J].
Gershoni-Baruch, R ;
Dagan, E ;
Fried, G ;
Kepten, I ;
Robinson, E .
EUROPEAN JOURNAL OF HUMAN GENETICS, 1999, 7 (07) :833-836
[7]   CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers [J].
Kadouri, L ;
Easton, DF ;
Edwards, S ;
Hubert, A ;
Kote-Jarai, Z ;
Glaser, B ;
Durocher, F ;
Abeliovich, D ;
Peretz, T ;
Eeles, RA .
BRITISH JOURNAL OF CANCER, 2001, 85 (01) :36-40
[8]   A single-nucleotide polymorphism in the RAD51 gene modifies breast cancer risk in BRCA2 carriers, but not in BRCA1 carriers or noncarriers [J].
Kadouri, L ;
Kote-Jarai, Z ;
Hubert, A ;
Durocher, F ;
Abeliovich, D ;
Glaser, B ;
Hamburger, T ;
Eeles, RA ;
Peretz, T .
BRITISH JOURNAL OF CANCER, 2004, 90 (10) :2002-2005
[9]   Polyglutamine repeat length in the AIB1 gene modifies breast cancer susceptibility in BRCA1 carriers [J].
Kadouri, L ;
Kote-Jarai, Z ;
Easton, DF ;
Hubert, A ;
Hamoudi, R ;
Glaser, B ;
Abeliovich, D ;
Peretz, T ;
Eeles, RA .
INTERNATIONAL JOURNAL OF CANCER, 2004, 108 (03) :399-403
[10]  
Kalbfleisch JD., 2011, STAT ANAL FAILURE TI